# A Study of PTX-9908 Injection for Non-resectable HCC with TACE

Source: https://onco.cc/trials/nct03812874/  
OnCo record `nct03812874` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PTX-9908 Injection in hepatocellular carcinoma, run by TCM Biotech International Corp., now recruiting.

## Summary

A Study of PTX-9908 Injection for Non-resectable HCC with TACE is a phase 1/2 interventional study registered as NCT03812874 by TCM Biotech International Corp., with 50 participants planned, started 2020-10-06 and due to reach its primary completion in 2026-08-30. Interventions recorded: PTX-9908 Injection and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03812874
- Phase: 1/2
- Setting: Phase I/II Study of PTX-9908 Injection As an Inhibitor of Cancer Progression in Patients with Non-resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment
- Sponsor: TCM Biotech International Corp.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT03812874: https://clinicaltrials.gov/study/NCT03812874

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct03812874.json